Literature DB >> 10536963

Alopecia areata: an autoimmune disease?

K J McElwee1, D J Tobin, J C Bystryn, L E King, J P Sundberg.   

Abstract

A wide range of hypotheses such as focal infection, trophoneuroses, and endocrine dysfunction, have been previously proposed to explain the pathogenesis of alopecia areata (AA). Currently, the most widely held belief is that AA is an autoimmune disease with cellular and/or humoral immunity directed against anagen hair follicle antigen(s). However, until recently evidence in support of an autoimmune mechanism of AA has been largely circumstantial. More fundamental evidence has recently been amassed in support of AA as an autoimmune disease by using animal models. These data include: 1) identification of cross-species hair follicle specific IgG autoantibodies, 2) The ability to induce AA in an animal model with transfer of skin from affected to naive individuals, and 3) the induction of disease by transfer of lymphocytes to human skin grafted to severe combined immunodeficiency mutant mice. A review of the previous and current data related to the autoimmune basis of AA is provided to put into perspective the future studies needed to definitively determine whether AA is an autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536963     DOI: 10.1111/j.1600-0625.1999.tb00385.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  16 in total

Review 1.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

2.  Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model.

Authors:  John P Sundberg; Kathleen A Silva; Weidong Zhang; Beth A Sundberg; Kathryn Edwards; Lloyd E King; Robert L Davis; Steven Black
Journal:  Vet Dermatol       Date:  2009-01-17       Impact factor: 1.589

3.  Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.

Authors:  M Zöller; P Freyschmidt-Paul; M Vitacolonna; K J McElwee; S Hummel; R Hoffmann
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

4.  An investigation of vitamin D status in alopecia areata.

Authors:  Venkata Krishna Vamsi Gade; Archana Mony; Malathi Munisamy; Laxmisha Chandrashekar; Medha Rajappa
Journal:  Clin Exp Med       Date:  2018-06-04       Impact factor: 3.984

5.  Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model.

Authors:  Xingqi Zhang; Mei Yu; Wayne Yu; Joanne Weinberg; Jerry Shapiro; Kevin J McElwee
Journal:  J Invest Dermatol       Date:  2008-11-20       Impact factor: 8.551

Review 6.  What causes alopecia areata?

Authors:  K J McElwee; A Gilhar; D J Tobin; Y Ramot; J P Sundberg; M Nakamura; M Bertolini; S Inui; Y Tokura; L E King; B Duque-Estrada; A Tosti; A Keren; S Itami; Y Shoenfeld; A Zlotogorski; R Paus
Journal:  Exp Dermatol       Date:  2013-09       Impact factor: 3.960

7.  An extraordinary colocalization of alopecia areata and vitiligo.

Authors:  Yuval Ramot; Elena Thomaidou; Alexander Mali; Abraham Zlotogorski
Journal:  Int J Trichology       Date:  2010-07

8.  Turban PUVASOL: An Effective Treatment in Alopecia Totalis.

Authors:  L Sornakumar; C Shanmuga Sekar; Cr Srinivas
Journal:  Int J Trichology       Date:  2010-07

9.  Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata.

Authors:  In Kwon Yeo; Eun Jung Ko; Yeon A No; Ee Seok Lim; Kui Young Park; Kapsok Li; Beom Joon Kim; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

10.  Efficacy of korean red ginseng in the treatment of alopecia areata.

Authors:  Ga Na Oh; Sang Wook Son
Journal:  J Ginseng Res       Date:  2012-10       Impact factor: 6.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.